HIV Management Guide for Clinical Care

HIV Management Guide for Clinical Care

Co-Morbidities

Management > Co-Morbidities > References

Sections

Sections

References

  1. Abraham AG, Althoff KN, Jing Y, et al. End-stage renal disease among HIV-infected adults in North America. Clinical Infectious Diseases 2014;60:941-9.
  2. Kalyesubula R, Hau JP, Asiki G, et al. Impaired renal function in a rural Ugandan population cohort. Wellcome Open Research 2018;3.
  3. Rosenberg AZ, Naicker S, Winkler CA, Kopp JB. HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment. Nature Reviews Nephrology 2015;11:150.
  4. Mallipattu SK, Salem F, Wyatt CM. The changing epidemiology of HIV-related chronic kidney disease in the era of antiretroviral therapy. Kidney international 2014;86:259-65.
  5. Gueler A, Moser A, Calmy A, et al. Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population. AIDS 2017;31:427.
  6. Phair J, Palella F. Renal disease in HIV infected Individuals. Current Opinion in HIV and AIDS 2011;6:285.
  7. Dummer PD, Limou S, Rosenberg AZ, et al. APOL1 kidney disease risk variants: an evolving landscape. Seminars in Nephrology; 2015: Elsevier. p. 222-36.
  8. Post FA, Holt SG. Recent developments in HIV and the kidney. Current Opinion in Infectious Diseases 2009;22:43-8.
  9. Wyatt CM, Murphy B. Kidney transplantation in HIV‐infected patients. Seminars in Dialysis; 2005: Wiley Online Library. p. 495-8.
  10. Jotwani V, Li Y, Grunfeld C, Choi AI, Shlipak MG. Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors. American Journal of Kidney Diseases 2012;59:628-35.
  11. Bansi L, Hughes A, Bhagani S, et al. Clinical epidemiology of HIV-associated end-stage renal failure in the UK. AIDS 2009;23:2517-21.
  12. Ekrikpo UE, Kengne AP, Bello AK, et al. Chronic kidney disease in the global adult HIV-infected population: A systematic review and meta-analysis. PloS One 2018;13:e0195443.
  13. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function—measured and estimated glomerular filtration rate. New England Journal of Medicine 2006;354:2473-83.
  14. Lucas GM, Lau B, Atta MG, Fine DM, Keruly J, Moore RD. Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. The Journal of Infectious Diseases 2008;197:1548-57.
  15. Health NIo. United States Renal Data System 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health 2011.
  16. Gracey D, Chan D, Bailey M, Richards D, Dalton B. Screening and management of renal disease in human immunodeficiency virus‐infected patients in Australia. Internal Medicine Journal 2013;43:410-6.
  17. Freedman BI, Limou S, Ma L, Kopp JB. APOL1-associated nephropathy: a key contributor to racial disparities in CKD. American Journal of Kidney Diseases 2018;72:S8-S16.
  18. Behar DM, Kedem E, Rosset S, et al. Absence of APOL1 risk variants protects against HIV-associated nephropathy in the Ethiopian population. American Journal of Nephrology 2011;34:452-9.
  19. Althoff KN, Gebo KA, Moore RD, et al. Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. The Lancet HIV 2019;6:e93-e104.
  20. Estrella MM, Fine DM. Screening for chronic kidney disease in HIV-infected patients. Advances in Chronic Kidney Disease 2010;17:26-35.
  21. Lucas GM, Ross MJ, Stock PG, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clinical Infectious Diseases 2014;59:e96-e138.
  22. García-García G, Gutiérrez-Padilla AJ, Chávez-Iñiguez J, Pérez-Gómez HR, Mendoza-García M, Tonelli M. Identifying undetected cases of chronic kidney disease in Mexico. Targeting high-risk populations. Archives of Medical Research 2013;44:623-7.
  23. Levey AS, Coresh J, Bolton K, et al. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American Journal of Kidney Diseases 2002;39.
  24. Levey A, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: approaches and initiatives–a position statement from Kidney Disease Improving Global Outcomes. Kidney International 2007;72:247-59.
  25. Gansevoort RT, Bakker SJ, De Jong PE. Early detection of progressive chronic kidney disease: is it feasible? : Am Soc Nephrol; 2006.
  26. Barraclough K, Er L, Ng F, Harris M, Montaner J, Levin A. A comparison of the predictive performance of different methods of kidney function estimation in a well-characterized HIV-infected population. Nephron Clinical Practice 2009;111:c39-c48.
  27. Yin J, Wang J. Renal drug transporters and their significance in drug–drug interactions. Acta Pharmaceutica Sinica B 2016;6:363-73.
  28. Deckert A, Neuhann F, Klose C, et al. Assessment of renal function in routine care of people living with HIV on ART in a resource-limited setting in urban Zambia. PloS One 2017;12:e0184766.
  29. European AIDS Clinical Society Guidelines. (Accessed August, 2019, at http://www.eacsociety.org/files/2018_guidelines-9.1-english.pdf.)
  30. Holt SG, Gracey DM, Levy MT, et al. A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection. AIDS Research and Therapy 2014;11:35.
  31. Wyatt CM. Kidney disease and HIV infection. Topics in antiviral medicine 2017;25:13.
  32. Wyatt CM, Klotman PE, D’Agati VD. HIV-associated nephropathy: clinical presentation, pathology, and epidemiology in the era of antiretroviral therapy. Seminars in Nephrology; 2008: Elsevier. p. 513-22.
  33. Da Silva D, Gluz I, Kurz J, et al. Multiple facets of HIV-associated renal disease. Brazilian Journal of Medical and Biological Research 2016;49.
  34. Jotwani V, Atta MG, Estrella MM. Kidney disease in HIV: Moving beyond HIV-associated nephropathy. Journal of the American Society of Nephrology 2017;28:3142-54.
  35. He L, Wei Q, Liu J, et al. AKI on CKD: heightened injury, suppressed repair, and the underlying mechanisms. Kidney International 2017;92:1071-83.
  36. Ellis CL. HIV associated kidney diseases: Clarifying concordance between renal failure in HIV infection and histopathologic manifestations at kidney biopsy. Seminars in Diagnostic Pathology; 2017: Elsevier. p. 377-83.
  37. Swanepoel CR, Atta MG, D’Agati VD, et al. Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International 2018;93:545-59.
  38. D’Agati V, Suh J-I, Carbone L, Cheng J-T, Appel G. Pathology of HIV-associated nephropathy: a detailed morphologic and comparative study. Kidney international 1989;35:1358-70.
  39. Smith MC, Pawar R, Carey JT, et al. Effect of corticosteroid therapy on human immunodeficiency virus-associated nephropathy. American Journal of Medicine 1994;97:145-51.
  40. Berliner AR, Fine DM, Lucas GM, et al. Observations on a cohort of HIV-infected patients undergoing native renal biopsy. American Journal of Nephrology 2008;28:478-86.
  41. Kimmel P, Phillips T, Ferreira-Centeno A, Farkas-Szallasi T, Abraham A, Garrett C. Brief report: Idiotypic IgA nephropathy in patients with HIV infection. N Engl J Med 1992;327:702-4.
  42. Haas M, Kaul S, Eustace JA. HIV-associated immune complex glomerulonephritis with “lupus-like” features: a clinicopathologic study of 14 cases. Kidney International 2005;67:1381-90.
  43. Lagathu C, Cossarizza A, Béréziat V, Nasi M, Capeau J, Pinti M. Basic science and pathogenesis of ageing with HIV: potential mechanisms and biomarkers. Aids 2017;31:S105-S19.
  44. Nix LM, Tien PC. Metabolic syndrome, diabetes, and cardiovascular risk in HIV. Current HIV/AIDS Reports 2014;11:271-8.
  45. Ryom L, Mocroft A, Lundgren J. HIV therapies and the kidney: some good, some not so good? Current HIV/AIDS Reports 2012;9:111-20.
  46. Acquah R, Graham H, Winter A. Quantifying polypharmacy in a large HIV‐infected cohort. HIV Medicine 2015;16:583-4.
  47. Woodward C, Hall A, Williams I, et al. Tenofovir‐associated renal and bone toxicity. HIV Medicine 2009;10:482-7.
  48. Hamzah L, Jose S, Booth J, et al. Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate. Journal of Infection 2017;74:492-500.
  49. Aloy B, Tazi I, Bagnis CI, et al. Is tenofovir alafenamide safer than tenofovir disoproxil fumarate for the kidneys? AIDS Rev. 2016; 18:184-192.
  50. De Clercq E. Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections. Biochemical Pharmacology 2018;153:2-11.
  51. Greene M, Steinman MA, McNicholl IR, Valcour V. Polypharmacy, drug–drug interactions, and potentially inappropriate medications in older adults with human immunodeficiency virus infection. Journal of the American Geriatrics Society 2014;62:447-53.
  52. Allavena C, Hanf M, Rey D, et al. Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients. PloS One 2018;13:e0203895.
  53. Llibre JM, Hung C-C, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. The Lancet 2018;391:839-49.
  54. Shahmanesh M, Schultze A, Burns F, et al. The cardiovascular risk management for people living with HIV in Europe: how well are we doing? AIDS 2016;30:2505-18.
  55. Naicker S, Rahmania S, Kopp JB. HIV and chronic kidney disease. Clinical Nephrology 2015;83:S32.
  56. Ahuja TS, Collinge N, Grady J, Khan S. Is dialysis modality a factor in survival of patients with ESRD and HIV-associated nephropathy? American Journal of Kidney Diseases 2003;41:1060-4.
  57. Locke JE, Mehta S, Reed RD, et al. A national study of outcomes among HIV-infected kidney transplant recipients. Journal of the American Society of Nephrology 2015;26:2222-9.
  58. Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. New England Journal of Medicine 2010;363:2004-14.

Developing a sustainable HIV, Viral Hepatitis and Sexual Health Workforce

Information

About ASHMFeedback
Glossary of TermsPrivacy Policy
AcknowledgementsDisclosure Statements

Acknowledgement of Country

We pay our respects to the Aboriginal and Torres Strait Islander peoples of the past, present, and future, including the Gadigal peoples (Sydney office), the Turrbal and Jagera/Yuggera peoples (Brisbane office), and all First Nations people of the nations where we live and work.

ASHM Health | ABN 48 264 545 457 | CFN 17788 | Copyright © 2024 ASHM

Scroll to Top